ESK-001, a TYK2 inhibitor, showed promising efficacy and good tolerability in phase 2 for plaque psoriasis, prompting a phase 3 trial.
The post Excellent Long-Term Data for TYK2 Inhibitor ESK-001 in Psoriasis first appeared on Physician’s Weekly.
ESK-001, a TYK2 inhibitor, showed promising efficacy and good tolerability in phase 2 for plaque psoriasis, prompting a phase 3 trial.
The post Excellent Long-Term Data for TYK2 Inhibitor ESK-001 in Psoriasis first appeared on Physician’s Weekly.
© 2023 blackandmed
© 2023 blackandmed